Table 3.
Standardised rate ratios based on age-standardised prevalence rates comparing pre- and post-vaccination LA estimates and post-vaccination estimates between LA, cobas and other monitoring strategies.
| HPV type | Standardised Rate Ratios |
||||
|---|---|---|---|---|---|
| LA (post-vaccination) vs. WHINURS LA (pre-vaccination) (95%CI) | cobas vs. LA (95%CI) | cobas/LA vs. LA (95%CI) | Alg. A vs LA (95%CI) | Alg. B vs. LA (95%CI) | |
| HPV16 | 0.33 (0.21–0.52) | 0.83 (0.50–1.34) | 0.95 (0.59–1.53) | 1.15 (0.73–1.83) | 0.79 (0.48–1.31) |
| HPV16/18 | 0.34 (0.23–0.59) | 0.90 (0.60–1.34) | 0.98 (0.66–1.45) | 1.17 (0.81–1.71) | 0.80 (0.53–1.21) |
| Non-16/18 HPV types | 0.68 (0.55–0.84) | 0.94 (0.79–1.13) | 0.93 (0.77–1.11) | 1.14 (0.96–1.35) | 0.79 (0.65–0.96) |
| HPV types in 9V vaccine (16,18, 31, 33, 45, 52, 58) | Not applicable* | Not applicable * | 0.88 (0.70–1.10) | Not applicable * | 0.60 (0.47–0.77) |
| Non-16/18 HPV in 9V vaccine (31,33, 45,52,58) | Not applicable* | Not applicable * | 0.83 (0.62–1.11) | Not applicable * | 0.84 (0.63–1.12) |
| All oncogenic HPV | 0.58 (0.48–0.69) | 0.93 (0.79–1.10) | 0.93 (0.79–1.10) | 1.14 (0.98–1.34) | 0.79 (0.67–0.94) |
*Prevalence for HPV types included in the nonavalent vaccine could not be determined as positivity for non-16/18 HPV positive samples is pooled and cannot distinguish between individual HPV types for cobas; similarly, results provided by WHINURS for non-16/18 types were pooled.